K. Weber et al., "Myocardial Fibrosis, Aldosterone, and Antialdosterone Therapy: Evolving Concepts in the Management of Congestive Heart Failure", Department of Medicine, University of Missouri-Columbia, pp. 1-33 (1991). |
Highlights Report #1, The XIIIth Congress of the European Society of Cardiology (Amsterdam, The Netherlands) pp. 1-4 (Aug., 1991). |
Remington's Pharmaceutical Sciences, 15th edition 1975, pp. 867-868. |
Doering, C.W., et al., "Collagen network remodeling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy," Cardiovasc. Res. 22: 686-695 (1988). |
Brilla, C.G., et al., "Remodeling of the rat right and left ventricle in experimental hypertension," Circ. Res. 67: 1355-1364 (1990). |
Weber, K.T., et al., "Structural remodeling of myocardial collagen in systemic hypertension: functional consequences and potential therapy," Heat Failure 6: 129-137 (1990). |
Weber, K.T., et al., "Myocardial remodeling and pathologic hypertrophy," Hospital Practice 26 (4): 73-80 (1991). |
Andreoli, T.E., "Introduction: Modern aspects of congestive heart failure," Hospital Practice 26(4): 7-8 (1991). |
Brilla, C.G., et al., abstract, "Myocardial fibrosis in experimental hypertension: potential role of fibroblast corticoid receptors," J. Hypertension 8: S8 (1990). |
Weber, K.T., and Brilla, C.G., "Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system" Circulation 83: 1849-1865 (Jun. 1991). |
Weber, K.T., and Brilla, C.G., "Myocardial fibrosis and elevations in plasma aldosterone in arterial hypertension," Aldosterone: Fundamental Aspects 215: 117-120 (1991). |
Brilla, C.G., and WEber, K. T., "Prevention of mycoardial fibrosis in hypertension: role of fibroblast corticoid receptors and spironolactone" Proceedings of the 75th Annual Meeting of the Fed. of Amer. Societies for Exper. Biology, 1991, abstract No. A1256, published Apr. 21, 1991. |
American Journal of Cardiology, Klug et al., "Role of Mechanical and Hormonal Factors in Cardiac Remodeling and the Biologic Limits of Myocardial Adaptation," Jan. 21, 1993, vol. 71, No. 3, pp. 46A-54A. |
Journal of Molecular and Cellular Cardiology, Brilla et al., "Anti-Aldosterone Treatment and the Prevention of Myocardial Fibrosis in Primary and Secondary Hyperaldosteronism," May 1993, vol. 25, No. 5, pp. 563-575. |
American Journal of Cardiology, Brilla et al., "Antifibrotic Effects of Spironolactone in Preventing Myocardial Fibrosis in Systemic Arterial Hypertension," Jan. 21, 1993, vol. 71, No. 3, pp. 12A-16A. |
Journal of Pharmacology and Experimental Therapeutics, "Three New Epoxy-Spirolactone Derivatives: Characterization in vivo and in vitro," Feb. 1987, vol. 240, No. 2, pp. 650-656. |
Bundesverbrand D. Pharm. Ind. E. V., "Rote Liste," 1987 Editio Cantor Aulendorf/Wurtt. |
J. Pharm. Exper. Ther. de Gasparo et al, 240(2) 650-656, 1987. |
J. Hypertension, Brilla et al, 8(13) 58, 1990. |